Physician profile
Sheldon Rabin
NPI 1922192343
$3,925.74
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $1,454 · 2021: $351 · 2022: $474 · 2023: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $1,898.81 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $357.46 | 2022-2023 | Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $250.40 | 2019-2021 | |
| Allergan, INC. | $245.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $222.13 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.03 | 2019-2021 | |
| Alcon Vision LLC | $196.36 | 2022-2023 | Rhopressa, Rocklatan, Simbrinza |
| Abbvie INC. | $193.66 | 2022-2023 | |
| Shire North American Group INC | $178.78 | 2019 | |
| Oyster Point Pharma, INC. | $98.26 | 2022 | |
| Dompe US, INC. | $42.39 | 2022 | |
| Eyevance Pharmaceuticals LLC | $21.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Rabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.